Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS)

BioDrugs - United Kingdom
doi 10.1007/s40259-018-0285-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search